El Helali, Aya http://orcid.org/0000-0001-6427-114X
Plummer, Ruth
Jayson, Gordon C.
Coyle, Vicky M.
Drew, Yvette
Mescallado, Nerissa
Harris, Noor
Clamp, Andrew R.
McCann, Janine
Swaisland, Helen
Kennedy, Richard D.
Cranston, Aaron N.
Wilson, Richard H. http://orcid.org/0000-0001-8018-7730
Funding for this research was provided by:
Cancer Research UK
Invest Northern Ireland
Article History
Received: 17 May 2021
Revised: 15 February 2022
Accepted: 2 March 2022
First Online: 14 May 2022
Competing interests
: Dr. AEH was awarded a travel bursary from Almac Discovery to present at ESMO 2017. Professor Richard Wilson received funding from Almac Discovery in 2014–2017 to support a clinical research fellowship. Professor RK is employed by Almac as the Medical Director. Dr. ANC is an employee of Almac Discovery. Dr. HS was paid a consultancy fee for advice and help with data analysis. The remaining authors declare no competing interests.
: The study was conducted per the International Council for Harmonisation (ICH) Good Clinical Practice (GCP), the principles of the Declaration of Helsinki, the European Union (EU) Clinical Trials Directive 2001/20/EC, the GCP Directive 2005/28/EC, and the requirements of the Independent Ethics Committee (IECs). The study was approved by the IEC and Medicines and Healthcare Products Regulatory Agency (MHRA). EudraCT No.: 2014-001175-31. The NCT trial number for this Phase I trial is NCT03427073. Written informed consent was required from all patients prior to enrolment.
: Consent for publication of images was provided by the patient.